您的位置: 首页 > 2025年3月 第56卷 第3期 > 文字全文
2023年7月 第38卷 第7期11
目录

ApoE 基因多态性与大动脉粥样硬化型脑梗死及卒中后认知障碍的相关性研究

Correlation of ApoE gene polymorphisms with large artery atherosclerotic cerebral infarction and post-stroke cognitive impairment

来源期刊: 广州医药 | 338-345 发布时间:2025-03-20 收稿时间:2025/4/9 17:39:33 阅读量:150
作者:
关键词:
ApoE基因多态性 大动脉粥样硬化型 脑梗死卒中后认知障碍易感基因等位基因
ApoE gene polymorphismlarge artery atheroscleroticcerebral infarctionpost-stroke cognitive impairmentsusceptibility geneallele gene
DOI:
10. 20223 / j. cnki. 1000-8535. 2025. 03. 007
收稿时间:
2024-08-28 
修订日期:
 
接收日期:
 
引用总数:
0  
      目的   探讨载脂蛋白E(ApoE)基因多态性与卒中后认知障碍的相关性,即大动脉粥样硬化型脑梗塞的严重程度。方法   采用病例——对照研究的方法,收集九江学院附属医院神经内科的100例急性缺血性脑卒中且病因分型为大动脉粥样硬化型患者(脑梗死组)和50例性别、年龄匹配的非缺血性脑卒中患者(对照组)。检测患者的 ApoE 基因型、血脂、美国国立卫生院卒中量表(NIHSS)、卒中后6个月简易智力状态检查量表(MMSE)等,采用多因素方差分析等统计学方法分析他们之间的关联性。结果  ApoE 3/4基因型频率与Ɛ3、Ɛ4等位基因频率,在脑梗死组别中高于对照组(P<0.05)。同时,携带Ɛ3等位基因患者的低密度脂蛋白水平高于携带Ɛ2、Ɛ4等位基因的患者;进一步分析发现含Ɛ3等位基因的脑梗死患者NIHSS评分更高、卒中后认知障碍更严重(P<0.05)。结论  ApoE基因型为Ɛ3/4、等位基因Ɛ3、Ɛ4更易罹患大动脉粥样硬化型脑梗死,提示该基因型是脑梗死的易感基因,脑梗死后认知障碍患者Ɛ3等位基因的频率较高,可能是卒中后认知障碍的易感因素。
       Objective  To  explore the  relationship  between ApoE  gene  polymorphisms  and  post-stroke  cognitive  impairment,the severity of large artery atherosclerotic cerebral infarction.Methods  A  case-control research  study was conducted,gathering  data from  100 individuals  diagnosed with large artery atherosclerotic cerebral infarction according to the TOAST classification,who admitted to the Neurology Department of the Affiliated Hospital of Jiujiang University.Additionally,50 non-ischemic stroke patients,matched for gender and age,were included as the control group.The patients were assessed for ApoE genotype,blood lipid,NIHSS,and MMSE scale at 6 months post-stroke,and statistical methods were used to analyze their associations.  Results  Significant differences were observed in the ApoE 3/4 genotype frequency and Ɛ3、Ɛ4 allele frequency between patients with cerebral infarction and the control group,with a notably higher incidence of cerebral infarction in the former.Furthermore,patients carrying the Ɛ3 allele exhibited significantly higher LDL levels than those carrying Ɛ2 or Ɛ4.The analysis also revealed that patients with the Ɛ4 allele experienced higher NIHSS and severer post-stroke cognitive impairment.Conclusions  The findings suggest that the ApoE genotype Ɛ3/4 and allele Ɛ3、Ɛ4 may predispose individuals to develop large atherosclerotic cerebral infarction,indicating a susceptibility gene for cerebral infarction.Additionally,the Ɛ3 allele was associated with a higher frequency of cognitive deficits after cerebral infarction,implying that it may be a predisposing factor for post-stroke cognitive impairment.
       脑梗死是指由于脑部血液循环的严重障碍,导致特定区域的脑组织因供血不足和氧气匮乏而遭受不可逆的损害,并伴随相应神经系统的功能缺损[1]。在全球范围内,急性缺血性脑卒中实验(Trial of Org 10 172 in Acute Stroke Treatment,TOAST)分类框架作为识别脑梗死病因的方法,将此类疾病细化为五大类[2],其中,大动脉粥样硬化型因其高发性而备受关注[3]。进一步深入探究揭示,众多风险因素交织作用,共同推高了大动脉粥样硬化的风险阈值。这些因素包括但不限于高龄、性别差异、糖尿病、高血压、同型半胱氨酸水平异常、血脂代谢失调、遗传因素、吸烟习惯、酒精摄入以及体质量管理失当等[4-5]。值得注意的是,有效管理高血压、糖尿病及血脂异常等基础性健康状态,已被多项研究证实为显著降低脑卒中风险的关键途径[6]。近期的科学探索重点逐渐集中于载脂蛋白E(apolipoprotein E,ApoE)基因的多样性[7-8],这一突破性发现不仅阐明了其在血脂异常和大动脉粥样硬化发展中的关键角色,还指出了其可能作为大动脉粥样硬化相关脑梗死基因遗传方向的潜在诱因[9-11]。此外,ApoE基因多样性的研究已经扩展到脑血管疾病之外,研究发现其与轻度认知障碍及阿尔茨海默病等神经退行性病变的密切相关,预示着其在这些疾病的预测、预防及干预策略制定中的潜在价值[12]
       鉴于此,本研究旨在探索ApoE基因多态性对大动脉粥样硬化型脑梗死患者神经功能的影响及卒中后认知功能的关系,以期为ApoE基因多态性在评估此类脑梗死亚型的风险预测与预后管理中的应用提供坚实的科学依据,从而推动个体化医疗策略的发展与实施。

1  资料与方法

1.1  研究对象

       本研究共纳入2019年1月—2020年12月医院收治的100例急性大动脉粥样硬化性脑梗死患者为脑梗死组。同时,为确保研究的严谨性,选择50名性别与年龄均与脑梗死组患者相匹配的健康个体为对照组。脑梗死组的纳入标准严格遵循以下两项核心条件:首要条件为患者经血管影像学检查证实,存在颅内或颅外大动脉狭窄超过50%,且这些狭窄与脑梗死引发的神经功能损伤具有一致性,同时动脉粥样硬化的病理特征与观察到的血管病变特征相吻合;次要条件为患者至少具备一项高危因素,例如高血压、糖尿病或血脂异常等。脑梗死组的排除标准:患有严重心脏病、近期有急性心肌梗死或心绞痛病史、严重肝肾功能障碍、严重感染或恶性肿瘤的患者;TOAST分型被归类为心源性栓塞、小动脉闭塞型、其他已知原因或原因未明的脑梗死患者;以及在发病前已表现出认知障碍症状的患者(简易智力状态检查量表(Mini-Mental State Examination,MMSE)评分<26分)。对照组的纳入标准则限定为:同期在本院接受健康体检的个体,并且排除了那些具有脑血管病史或脑血管病家族史的参与者。本研究方案已经获得医院伦理委员会的批准,患者及家属均签署知情同意书(批件号:九医伦-2018-012)。

1.2  仪器和试剂

      DNA提取试剂盒(天根试剂盒)、PCRmix(2X-P6 High-Fidelity mix)、PCR扩增仪、3.0 T MRI(西门子)、256层螺旋CT(飞利浦)和DSA(飞利浦)手术室。

1.3  基因检测方法

       采集每位患者2 mLEDTA抗凝的外周静脉血样,并将其分配到两个试管中,以提取人类基因组DNA。采用聚合酶链式反应限制性片段长度多态性(restriction fragment length polymorphism,PCR-RFLP)技术来检测ApoE基因的多态性。同时,使用天根生化科技有限公司提供的试剂盒,并结合盐析法来同步提取DNA,操作过程严格遵循产品说明书步骤。
      PCR使用了PCR mix扩增ApoE基因的rs429358和rs7412这两个特定的位点。PCR的循环条件具体如下:(1)95 ℃ 5 min预处理;(2)在95 ℃30 s变性、66 ℃ 30 s退火、72 ℃ 50 s延伸共3次;(3)95 ℃ 30 s,58 ℃ 30 s退火,72 ℃ 50 s延伸,共30次;(4)72 ℃ 5 min延伸。PCR产物测序由广州金域医学检验集团股份有限公司和明琛志远生物技术(北京)有限公司合成。

1.4  临床资料收集

       收集研究对象的详细资料,包括性别、年龄、既往病史(具体涵盖高血压、冠心病、糖尿病等)、吸烟习惯、饮酒情况、教育水平、各项血液指标、神经功能评分量表的数据。对于脑梗死患者,记录其发病后6个月的MMSE评分。采用以下标准评估卒中后认知障碍:对于小学及以下学历的研究对象,MMSE评分≤17分被视为存在认知障碍;而对于中学及以上学历的研究对象,MMSE评分≤24分则被视为存在认知障碍。

1.5  统计学方法

       利用SPSS 26.0软件对数据进行了详尽的统计分析。对于连续性变量,采用均值和标准差(均值±标准差)的形式来展示,并运用独立样本t检验来评估两组间均值的差异是否具有统计学意义。对于分类变量通过计算百分比来描述其分布,并采用χ 2 检验来分析变量间的关联性。进一步探究不同群体间均值差异,采用多因素方差分析(ANOVA)。此外,为了深入理解ApoE基因多态性与卒中后认知障碍之间的潜在联系,采用了Logistic回归模型进行分析。在所有统计检验中,P<0.05表示差异具有统计学意义。

2  结 果

2.1  两组患者基线特点

       在本研究中,从521例脑梗死患者中筛选100例符合大动脉粥样硬化型脑梗死条件的患者作为研究对象,男女比例均衡(58∶42),平均年龄为(66.3±9.7)岁。同时,本研究设立了对照组,包括50名正常人,男女比例同样为1∶1(25∶25),平均年龄为(64.5±7.7)岁。
       脑梗死组在生化指标如甘油三酯、总胆固醇、低密度脂蛋白、同型半胱氨酸、葡萄糖和糖化血红蛋白等水平高于对照组。两组患者的年龄、性别、教育水平、体质指数(body  mass index,BMI)、吸烟习惯、饮酒习惯、高血压、糖尿病和高密度脂蛋白胆固醇之间的差异无统计学意义。(见表1)。 
20250415114057_6499.png

2.2  ApoE基因多态性及其等位基因的分布特征比

       与对照组相比,ApoE基因型检测结果Ɛ2/2、Ɛ2/3、Ɛ2/4和Ɛ3/3四种基因型无明显差异。而脑梗死组Ɛ3/4和Ɛ4/4这两种基因型的频率高于对照组。进一步分析发现,Ɛ3/ Ɛ4是脑梗死组中最常见的基因型,占比高达42%,Ɛ3/ Ɛ3是对照组中最常见的基因型,占比为48%。此外,课题组还发现对照组Ɛ3/ Ɛ4、Ɛ4/ Ɛ4基因型的分布构成比低于脑梗死组患者(P<0.05)。
       ApoE Ɛ 2/2 、 ApoE Ɛ 3/3 、 ApoE Ɛ 4/4 、ApoEƐ2/3、ApoEƐ3/4和ApoEƐ2/4是ApoE蛋白中三种异构体组合形成的六种不同表型。与以往的研究结果一致,在正常人群中,ApoEƐ2/2、ApoEƐ4/4和ApoEƐ2/4这三种表型的发生率相对较低,而ApoEƐ3/3的发生率则最高,是最常见的等位基因。在脑梗死组中,ApoEƐ3/3的发生率为48%,而在对照组中则为26%。此外,等位基因Ɛ2和Ɛ4,在两组中的分布也具有一定的特点。具体见表2。
20250415114122_8842.jpg

2.3  ApoE基因多态性与脑梗死后神经功能损伤的关系分析

       对100例脑梗死患者ApoE基因多态性与入院第一天的NIHSS评分进行比较。结果显示携带Ɛ3/4基因型的患者NIHSS评分最高,为9.53±3.57,携带Ɛ4/4基因型的患者NIHSS评分7.45±3.45,Ɛ2/2、Ɛ2/3、Ɛ2/4分别为0、5.34±3.34、6.03±2.92,但各基因型组间无明显差异。ApoE等位基因Ɛ2、Ɛ3、Ɛ4患者NIHSS评分分别为2.03±2.08、6.08±3.26、8.08±2.73,脑梗死神经功能损害最严重的是携带Ɛ4等位基因的患者(P<0.05)。 
20250415114156_3803.jpg

2.4  ApoE基因多态性与卒中后认知障碍的关联

       对脑梗死患者进行发病后6个月的随访,并采用MMSE评分评估其认知功能。结果显示,脑梗死后出现了认知障碍的患者有22例。进一步分析发现,携带Ɛ3/ Ɛ3和Ɛ3/ Ɛ4基因型的患者在出现认知障碍的患者中比例最高,分别为41%和45%,与不伴有认知障碍的患者组相比,Ɛ3/3基因型是引起脑梗死认知障碍的危险因素,差异有统计学意义(P<0.05)。
      为进一步分析脑梗死后认知障碍患者中基因型的分布,因此以等位基因Ɛ2、Ɛ3、Ɛ4在两组中的分布情况进行了进一步分析。结果显示,Ɛ3等位基因的频率在伴有认知障碍的脑梗死组中高于其他等位基因。同时,与未携带Ɛ3等位基因的患者相比,携带该等位基因的患者MMSE评分最低(15.39±2.36),且这一结果具有显著差异性(P<0.05)。这表明Ɛ3等位基因可能与脑梗死后的认知障碍的严重程度密切相关。见表4、图1。
20250415114233_3081.jpg

20250415114305_4761.png

图 1 不同等位基因组 MMSE 评分间比较
注:组间比较,* P<0.05。
       逻辑回归分析发现基线年龄、性别、高血压、糖尿病、低密度脂蛋白、D-二聚体、同型半胱氨酸、吸烟率等变量后,发现Ɛ3等位基因与卒中后认知障碍呈正相关(β=1.41,P<0.05),即携带Ɛ3等位基因的患者出现脑梗死后易发生认知障碍(表4)。大动脉粥样硬化型脑梗死患者认知障碍的危险因素是Ɛ3等位基因。

3  讨 论

       本研究发现,脑梗死患者ApoE基因型为Ɛ3/  Ɛ4(42%),等位基因是Ɛ3(80%);对照组ApoE基因型为Ɛ3/  Ɛ3(48%),等位基因是Ɛ3(60%)。研究表明,Ɛ3/ Ɛ4基因型和Ɛ3等位基因可能与大动脉粥样硬化性脑梗死后的认知障碍有关。本研究旨在探讨脑梗死后认知障碍的遗传背景,以便能够提前预防此类疾病的发生。
       脑卒中通常是由遗传因素和环境因素等多种内外因素的紊乱共同作用的结果[6],动脉粥样硬化是导致脑卒中的一个内在因素。在TOAST分型中,大动脉粥样硬化性脑梗死的发病率占据了显著的优势地位,且该型脑梗死与多种风险因素紧密相关,其中低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)被视为一个独立的危险因素[13]。当血液中的LDL-C浓度持续升高时,这些脂质成分容易沉积在心脑血管的动脉壁上,进而形成动脉粥样硬化斑块[14]。随着时间的推移,这些斑块可能逐渐增大并阻塞血管,导致血流减少,最终可能引发缺血性脑卒中及其他心血管疾病的发生[15]。ApoE作为载脂蛋白家族的重要成员,主要在肝脏中合成并积极参与机体的代谢过程[16]。它是一种多态性蛋白,具有Ɛ2、Ɛ3、Ɛ4三种等位基因,这些等位基因可以以不同的组合方式形成6种基因型,即Ɛ2/2、Ɛ2/3、Ɛ2/4、Ɛ3/3、Ɛ3/4、Ɛ4/4[17]。ApoE在脂蛋白的代谢和运输中发挥着关键作用,不仅与血浆脂蛋白水平密切相关,还对维持机体的血脂水平起着至关重要的作用[9,18]。在众多遗传标记中,ApoE基因可能是最具决定性的因素[19]。本研究结果显示,脑梗死患者ApoE基因型为Ɛ3/4脑梗死患者ApoE基因型Ɛ3/4(42%)是最多的,等位基因是Ɛ3为80%,表明在大动脉粥样硬化性脑梗死中,Ɛ3 基因属于遗传易感因子,本研究结果与Wang等[20]的实验结果是一致的。Yan等[21]的研究指出,ApoE的Ɛ2等位基因与个体的总胆固醇及低密度脂蛋白胆固醇水平呈逆相关,而Ɛ4等位基因则与脑梗死的风险正相关。这可能是因为ApoE作为胆固醇的运输载体,其功能减弱时会导致胆固醇在体内异常积累,从而增加心血管疾病的风险,如高血压和动脉粥样硬化,进而可能导致脑梗死。然而,Zhong[22]在分析中国人群时得到了不同的结论,他们发现ApoE的Ɛ3/Ɛ3和Ɛ3/Ɛ4基因型在男性中可能降低脑梗死的风险,而在女性中则未见此效应。此外,他们还观察到Ɛ2和Ɛ4基因型可能增加男性脑梗死的风险,而Ɛ3和Ɛ4基因型在女性中可能具有保护作用。本研究结果与其他不一样,这种差异可能与研究人群的地理分布和种族背景有关。ApoE基因的多态性可能是探索遗传背景与环境风险因素交互作用的一个重要指标[23]。因此,对于携带高风险等位基因Ɛ3的人群,尤其是那些暴露于多种环境风险因素的个体,应更加重视对这些因素的控制,以减少卒中的整体风险。
       近期的研究发现,ApoE基因的多态性在生物医学领域具有多种重要功能,尤其是该基因与认知功能损害之间的联系更是受到广泛关注[24-25]Davidson等[26]已经证明,拥有ApoE Ɛ4等位基因的个体,其罹患血管性痴呆的风险显著增加。Klages[27]研究进一步指出,在AD患者中,ApoE Ɛ4等位基因的出现频率最高,其次是血管性认知障碍但未达到痴呆程度(vascular cognitive impairment no dementia,VCIND)的患者,最后是对照组。Noguchi等[28]也支持这些结果。在AD的进展期,携带APOE Ɛ4等位基因的患者更有可能发展成血管性认知障碍[29]。这引发了一个关键问题:ApoE基因的多态性是否与大动脉粥样硬化型脑梗死患者随后出现的认知障碍存在关联?本研究发现脑梗死患者有22例出现认知障碍,其中携带Ɛ3/3和Ɛ3/4比例最高,分别为41%和45%,其中Ɛ3/3与不伴有认知障碍的患者比较差异具有统计学意义。国内研究者宋明芬等[30]在一项深入研究中,专门探讨了脑梗死后血管性痴呆(vascular dementia,VD)患者的ApoE基因多态性。他们发现,与健康人群相比,脑梗死后VD患者的ApoE Ɛ4等位基因频率显著更高,(30.38% vs 15.62%)。这种显著的差异暗示ApoE Ɛ4等位基因可能与脑梗死VD的发生及进展有着紧密的联系[31]。研究者推测,ApoE Ɛ4基因可能作为一个易感因素,在脑梗死后加速了患者认知功能的下降,从而更容易发展为VD。这项研究不仅提供了新的视角来理解脑梗死后认知功能下降的机制,还强调了ApoE Ɛ4基因在脑血管疾病后认知功能保护中的潜在重要作用[32]。展望未来,深入研究ApoE Ɛ4基因多态性可能会促进开发更加定制化的预防措施和治疗方案,这些措施和方案旨在减轻或推迟脑梗死患者认知功能衰退的过程,从而提升他们的生活质量。
      VD 是少数可以预防的痴呆类型之一[33]。及时识别、诊断并采取早期预防和治疗措施对于优化患者的治疗效果和提升其日常生活质量至关重要。针对携带Ɛ3/4基因型及Ɛ4等位基因的脑梗死患者,未来应采取更为积极的策略,即早期实施神经行为学与认知功能的筛查,及时开展认知康复训练与药物治疗,旨在有效降低这类患者卒中后发生认知障碍的风险。此举措对于优化患者预后、促进其认知功能恢复及提高整体生活质量具有重要意义,符合现代医学对于脑血管疾病综合管理与个性化治疗的发展趋势。
       本研究存在不足。首先是入组病例数偏少,脑梗死组100例,发生卒中后认知障碍的仅22例,可能存在数据偏倚;其次,卒中后认知障碍的危险因素较多,如脑梗死部位、梗死体积等,没有进行细分,也可能导致结果偏倚。为了克服前述的研究局限性,未来的研究将扩大样本规模或采用队列研究设计,并且将系统地收集及比较分析影响卒中后认知障碍的多种潜在风险因子,深入探究并证实Ɛ3对大动脉粥样硬化型脑梗死严重性及卒中后认知障碍的影响。
       总体而言,ApoE基因型Ɛ3/4和Ɛ3与大动脉粥样硬化型脑梗死的发病风险关系密切,这表明它们可能是该疾病的风险因素。同时,在脑梗死后出现认知障碍的患者中,Ɛ3等位基因的频率较高,这可能意味着它是卒中后认知障碍的一个易感因素。
1、中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国缺血性卒中和短暂性脑缺血发作二级预防指南2022[J].中华神经科杂志,2022,55(10):1071-1110.中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国缺血性卒中和短暂性脑缺血发作二级预防指南2022[J].中华神经科杂志,2022,55(10):1071-1110.
2、HUI%E2%80%83C%EF%BC%8CTADI%E2%80%83P%EF%BC%8CKHAN%E2%80%83S%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8EIschemic%E2%80%83stroke%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EFlorida%EF%BC%9AStatPearls%EF%BC%8C2024%EF%BC%8EHUI%E2%80%83C%EF%BC%8CTADI%E2%80%83P%EF%BC%8CKHAN%E2%80%83S%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8EIschemic%E2%80%83stroke%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EFlorida%EF%BC%9AStatPearls%EF%BC%8C2024%EF%BC%8E
3、%E2%80%83%20PARADOWSKI%E2%80%83B%EF%BC%8CMACIEJAK%E2%80%83A%EF%BC%8ET%20O%20A%20S%20T%E2%80%83%0Aclassification%E2%80%83of%E2%80%83subtypes%E2%80%83of%E2%80%83ischaemic%E2%80%83stroke%EF%BC%9Adiagnostic%E2%80%83%0Aand%E2%80%83therapeutic%E2%80%83procedures%E2%80%83in%E2%80%83stroke%EF%BC%9AA%E2%80%83four-year%E2%80%83%0Aobservation%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECerebrovasc%E2%80%83Dis%EF%BC%8C2005%EF%BC%8C20%0A%EF%BC%885%EF%BC%89%EF%BC%9A319-324%EF%BC%8E%E2%80%83%20PARADOWSKI%E2%80%83B%EF%BC%8CMACIEJAK%E2%80%83A%EF%BC%8ET%20O%20A%20S%20T%E2%80%83%0Aclassification%E2%80%83of%E2%80%83subtypes%E2%80%83of%E2%80%83ischaemic%E2%80%83stroke%EF%BC%9Adiagnostic%E2%80%83%0Aand%E2%80%83therapeutic%E2%80%83procedures%E2%80%83in%E2%80%83stroke%EF%BC%9AA%E2%80%83four-year%E2%80%83%0Aobservation%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECerebrovasc%E2%80%83Dis%EF%BC%8C2005%EF%BC%8C20%0A%EF%BC%885%EF%BC%89%EF%BC%9A319-324%EF%BC%8E
4、ROJSANGA%E2%80%83W%20%EF%BC%8C%20SAWANYAWISUTH%E2%80%83K%20%EF%BC%8CCHOTMONGKOL%E2%80%83V%EF%BC%8Cet%E2%80%83al%EF%BC%8EClinical%E2%80%83%20risk%E2%80%83factors%E2%80%83%0Apredictive%E2%80%83%20of%E2%80%83thrombotic%E2%80%83%20stroke%E2%80%83with%E2%80%83large%E2%80%83%20cerebral%E2%80%83%0Ainfarction%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENeurol%E2%80%83Int%EF%BC%8C2019%EF%BC%8C11%EF%BC%882%EF%BC%89%EF%BC%9A7941%EF%BC%8EROJSANGA%E2%80%83W%20%EF%BC%8C%20SAWANYAWISUTH%E2%80%83K%20%EF%BC%8CCHOTMONGKOL%E2%80%83V%EF%BC%8Cet%E2%80%83al%EF%BC%8EClinical%E2%80%83%20risk%E2%80%83factors%E2%80%83%0Apredictive%E2%80%83%20of%E2%80%83thrombotic%E2%80%83%20stroke%E2%80%83with%E2%80%83large%E2%80%83%20cerebral%E2%80%83%0Ainfarction%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENeurol%E2%80%83Int%EF%BC%8C2019%EF%BC%8C11%EF%BC%882%EF%BC%89%EF%BC%9A7941%EF%BC%8E
5、谷文龙,黄玉宇,王红武,等.代谢综合征与心血管疾病和痴呆的关系[J].广州医药,2017,48(4):51-55,59.谷文龙,黄玉宇,王红武,等.代谢综合征与心血管疾病和痴呆的关系[J].广州医药,2017,48(4):51-55,59.
6、BOEHME%E2%80%83A%E2%80%83K%EF%BC%8CESENWA%E2%80%83C%EF%BC%8CELKIND%E2%80%83M%E2%80%83S%E2%80%83V%EF%BC%8E%0AStroke%E2%80%83risk%E2%80%83factors%EF%BC%8Cgenetics%EF%BC%8Cand%E2%80%83prevention%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ACirc%E2%80%83Res%EF%BC%8C2017%EF%BC%8C120%EF%BC%883%EF%BC%89%EF%BC%9A472-495%EF%BC%8EBOEHME%E2%80%83A%E2%80%83K%EF%BC%8CESENWA%E2%80%83C%EF%BC%8CELKIND%E2%80%83M%E2%80%83S%E2%80%83V%EF%BC%8E%0AStroke%E2%80%83risk%E2%80%83factors%EF%BC%8Cgenetics%EF%BC%8Cand%E2%80%83prevention%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ACirc%E2%80%83Res%EF%BC%8C2017%EF%BC%8C120%EF%BC%883%EF%BC%89%EF%BC%9A472-495%EF%BC%8E
7、LANFRANCO%E2%80%83M%E2%80%83F%EF%BC%8CSEPULVEDA%E2%80%83J%EF%BC%8CKOPETSKY%E2%80%83%0AG%EF%BC%8Cet%E2%80%83al%EF%BC%8EExpression%E2%80%83and%E2%80%83secretion%E2%80%83of%E2%80%83apoE%E2%80%83isoforms%E2%80%83in%E2%80%83%0Aastrocytes%E2%80%83and%E2%80%83microglia%E2%80%83during%E2%80%83%E2%80%83inflammation%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AGlia%EF%BC%8C2021%EF%BC%8C69%EF%BC%886%EF%BC%89%EF%BC%9A1478-1493%EF%BC%8ELANFRANCO%E2%80%83M%E2%80%83F%EF%BC%8CSEPULVEDA%E2%80%83J%EF%BC%8CKOPETSKY%E2%80%83%0AG%EF%BC%8Cet%E2%80%83al%EF%BC%8EExpression%E2%80%83and%E2%80%83secretion%E2%80%83of%E2%80%83apoE%E2%80%83isoforms%E2%80%83in%E2%80%83%0Aastrocytes%E2%80%83and%E2%80%83microglia%E2%80%83during%E2%80%83%E2%80%83inflammation%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AGlia%EF%BC%8C2021%EF%BC%8C69%EF%BC%886%EF%BC%89%EF%BC%9A1478-1493%EF%BC%8E
8、WINDHAM%E2%80%83I%E2%80%83A%EF%BC%8CCOHEN%E2%80%83S%EF%BC%8EThe%E2%80%83%20cell%E2%80%83%20biology%E2%80%83%20of%E2%80%83%0AAPOE%E2%80%83in%E2%80%83the%E2%80%83brain%EF%BC%BBJ%EF%BC%BD%EF%BC%8ETrends%E2%80%83Cell%E2%80%83Biol%EF%BC%8C2024%EF%BC%8C%0A34%EF%BC%884%EF%BC%89%EF%BC%9A338-348%EF%BC%8EWINDHAM%E2%80%83I%E2%80%83A%EF%BC%8CCOHEN%E2%80%83S%EF%BC%8EThe%E2%80%83%20cell%E2%80%83%20biology%E2%80%83%20of%E2%80%83%0AAPOE%E2%80%83in%E2%80%83the%E2%80%83brain%EF%BC%BBJ%EF%BC%BD%EF%BC%8ETrends%E2%80%83Cell%E2%80%83Biol%EF%BC%8C2024%EF%BC%8C%0A34%EF%BC%884%EF%BC%89%EF%BC%9A338-348%EF%BC%8E
9、KUMAR%E2%80%83A%EF%BC%8CKUMAR%E2%80%83P%EF%BC%8CPRASAD%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAssociation%E2%80%83%20between%E2%80%83%20apolipoprotein%E2%80%83%20epsilon4%E2%80%83%20gene%E2%80%83%0Apolymorphism%E2%80%83and%E2%80%83risk%E2%80%83of%E2%80%83ischemic%E2%80%83stroke%EF%BC%9AA%E2%80%83meta%02analysis%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAnn%E2%80%83Neurosci%EF%BC%8C2016%EF%BC%8C23%EF%BC%882%EF%BC%89%EF%BC%9A%0A113-121%EF%BC%8EKUMAR%E2%80%83A%EF%BC%8CKUMAR%E2%80%83P%EF%BC%8CPRASAD%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAssociation%E2%80%83%20between%E2%80%83%20apolipoprotein%E2%80%83%20epsilon4%E2%80%83%20gene%E2%80%83%0Apolymorphism%E2%80%83and%E2%80%83risk%E2%80%83of%E2%80%83ischemic%E2%80%83stroke%EF%BC%9AA%E2%80%83meta%02analysis%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAnn%E2%80%83Neurosci%EF%BC%8C2016%EF%BC%8C23%EF%BC%882%EF%BC%89%EF%BC%9A%0A113-121%EF%BC%8E
10、YE%E2%80%83B%E2%80%83S%EF%BC%8CKIM%E2%80%83H%E2%80%83J%EF%BC%8CYOON%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8EP2%E2%80%93071%EF%BC%9A%0AEffects%E2%80%83of%E2%80%83APOE-%CE%B54%E2%80%83on%E2%80%83lacunar%E2%80%83infarcts%EF%BC%8Cwhite%E2%80%83matter%E2%80%83%0Alesions%E2%80%83and%E2%80%83brain%E2%80%83amyloid%EF%BC%9AA%E2%80%83study%E2%80%83among%E2%80%83people%E2%80%83with%E2%80%83%0Asubcortical%E2%80%83vascular%E2%80%83cognitive%E2%80%83impairment%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAlzheimers%E2%80%83Dement%EF%BC%8C2013%EF%BC%8C9%EF%BC%884S_Part_9%EF%BC%89%EF%BC%9A369-%0A370%EF%BC%8EYE%E2%80%83B%E2%80%83S%EF%BC%8CKIM%E2%80%83H%E2%80%83J%EF%BC%8CYOON%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8EP2%E2%80%93071%EF%BC%9A%0AEffects%E2%80%83of%E2%80%83APOE-%CE%B54%E2%80%83on%E2%80%83lacunar%E2%80%83infarcts%EF%BC%8Cwhite%E2%80%83matter%E2%80%83%0Alesions%E2%80%83and%E2%80%83brain%E2%80%83amyloid%EF%BC%9AA%E2%80%83study%E2%80%83among%E2%80%83people%E2%80%83with%E2%80%83%0Asubcortical%E2%80%83vascular%E2%80%83cognitive%E2%80%83impairment%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAlzheimers%E2%80%83Dement%EF%BC%8C2013%EF%BC%8C9%EF%BC%884S_Part_9%EF%BC%89%EF%BC%9A369-%0A370%EF%BC%8E
11、QUAN%E2%80%83M%EF%BC%8CLV%E2%80%83H%EF%BC%8CLIU%E2%80%83Z%EF%BC%8Cet%E2%80%83al%EF%BC%8EMST1%E2%80%83%20suppresses%E2%80%83%0Adisturbed%E2%80%83flow%E2%80%83induced%E2%80%83atherosclerosis%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECirc%E2%80%83%0ARes%EF%BC%8C2022%EF%BC%8C131%EF%BC%889%EF%BC%89%EF%BC%9A748-764%EF%BC%8EQUAN%E2%80%83M%EF%BC%8CLV%E2%80%83H%EF%BC%8CLIU%E2%80%83Z%EF%BC%8Cet%E2%80%83al%EF%BC%8EMST1%E2%80%83%20suppresses%E2%80%83%0Adisturbed%E2%80%83flow%E2%80%83induced%E2%80%83atherosclerosis%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECirc%E2%80%83%0ARes%EF%BC%8C2022%EF%BC%8C131%EF%BC%889%EF%BC%89%EF%BC%9A748-764%EF%BC%8E
12、ZHANG%E2%80%83H%EF%BC%8CZHAO%E2%80%83X%20%EF%BC%8CWANG%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AA%E2%80%83%20preliminary%E2%80%83%20study%E2%80%83%20of%E2%80%83%20the%E2%80%83%20association%E2%80%83%20between%E2%80%83%0Aa%20p%20oli%20p%20o%20p%20r%20ot%20ei%20n%E2%80%83%20E%E2%80%83%20p%20r%20o%20m%20ot%20e%20r%E2%80%83%20m%20et%20h%20yl%20ati%20o%20n%E2%80%83%20a%20n%20d%E2%80%83%0Aatherosclerotic%E2%80%83cerebral%E2%80%83infarction%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%20Stroke%E2%80%83%0ACerebrovasc%E2%80%83Dis%EF%BC%8C2019%EF%BC%8C28%EF%BC%884%EF%BC%89%EF%BC%9A1056-1061%EF%BC%8EZHANG%E2%80%83H%EF%BC%8CZHAO%E2%80%83X%20%EF%BC%8CWANG%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AA%E2%80%83%20preliminary%E2%80%83%20study%E2%80%83%20of%E2%80%83%20the%E2%80%83%20association%E2%80%83%20between%E2%80%83%0Aa%20p%20oli%20p%20o%20p%20r%20ot%20ei%20n%E2%80%83%20E%E2%80%83%20p%20r%20o%20m%20ot%20e%20r%E2%80%83%20m%20et%20h%20yl%20ati%20o%20n%E2%80%83%20a%20n%20d%E2%80%83%0Aatherosclerotic%E2%80%83cerebral%E2%80%83infarction%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%20Stroke%E2%80%83%0ACerebrovasc%E2%80%83Dis%EF%BC%8C2019%EF%BC%8C28%EF%BC%884%EF%BC%89%EF%BC%9A1056-1061%EF%BC%8E
13、NELSON%E2%80%83K%EF%BC%8CFUSTER%E2%80%83V%EF%BC%8CRIDKER%E2%80%83P%E2%80%83M%EF%BC%8ELow-dose%E2%80%83%0Acolchicine%E2%80%83for%E2%80%83secondary%E2%80%83prevention%E2%80%83of%E2%80%83coronary%E2%80%83artery%E2%80%83%0Adisease%EF%BC%9AJACC%E2%80%83%E2%80%83review%E2%80%83topic%E2%80%83of%E2%80%83the%E2%80%83week%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Am%E2%80%83%0AColl%E2%80%83Cardiol%EF%BC%8C2023%EF%BC%8C82%EF%BC%887%EF%BC%89%EF%BC%9A648-660%EF%BC%8ENELSON%E2%80%83K%EF%BC%8CFUSTER%E2%80%83V%EF%BC%8CRIDKER%E2%80%83P%E2%80%83M%EF%BC%8ELow-dose%E2%80%83%0Acolchicine%E2%80%83for%E2%80%83secondary%E2%80%83prevention%E2%80%83of%E2%80%83coronary%E2%80%83artery%E2%80%83%0Adisease%EF%BC%9AJACC%E2%80%83%E2%80%83review%E2%80%83topic%E2%80%83of%E2%80%83the%E2%80%83week%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Am%E2%80%83%0AColl%E2%80%83Cardiol%EF%BC%8C2023%EF%BC%8C82%EF%BC%887%EF%BC%89%EF%BC%9A648-660%EF%BC%8E
14、XU%E2%80%83D%EF%BC%8CXIE%E2%80%83L%EF%BC%8CCHENG%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8ETriglyceride-rich%E2%80%83%0Alipoproteins%E2%80%83and%E2%80%83cardiovascular%E2%80%83diseases%EF%BC%BBJ%EF%BC%BD%EF%BC%8EFront%E2%80%83%0AEndocrinol%EF%BC%8C2024%EF%BC%8815%EF%BC%89%EF%BC%9A1409653%EF%BC%8EXU%E2%80%83D%EF%BC%8CXIE%E2%80%83L%EF%BC%8CCHENG%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8ETriglyceride-rich%E2%80%83%0Alipoproteins%E2%80%83and%E2%80%83cardiovascular%E2%80%83diseases%EF%BC%BBJ%EF%BC%BD%EF%BC%8EFront%E2%80%83%0AEndocrinol%EF%BC%8C2024%EF%BC%8815%EF%BC%89%EF%BC%9A1409653%EF%BC%8E
15、SACKS%E2%80%83F%E2%80%83M%EF%BC%8CFURTADO%E2%80%83J%E2%80%83D%EF%BC%8CJENSEN%E2%80%83M%E2%80%83K%EF%BC%8E%0AProtein-based%E2%80%83HDL%E2%80%83subspecies%EF%BC%9ARationale%E2%80%83%20and%E2%80%83%0Aassociation%E2%80%83with%E2%80%83cardiovascular%E2%80%83disease%EF%BC%8Cdiabetes%EF%BC%8Cstroke%EF%BC%8Cand%E2%80%83dementia%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiochim%E2%80%83Biophys%E2%80%83Acta%E2%80%83%0AMol%E2%80%83Cell%E2%80%83Biol%E2%80%83Lipids%EF%BC%8C2022%EF%BC%8C1867%EF%BC%889%EF%BC%89%EF%BC%9A159182%EF%BC%8ESACKS%E2%80%83F%E2%80%83M%EF%BC%8CFURTADO%E2%80%83J%E2%80%83D%EF%BC%8CJENSEN%E2%80%83M%E2%80%83K%EF%BC%8E%0AProtein-based%E2%80%83HDL%E2%80%83subspecies%EF%BC%9ARationale%E2%80%83%20and%E2%80%83%0Aassociation%E2%80%83with%E2%80%83cardiovascular%E2%80%83disease%EF%BC%8Cdiabetes%EF%BC%8Cstroke%EF%BC%8Cand%E2%80%83dementia%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiochim%E2%80%83Biophys%E2%80%83Acta%E2%80%83%0AMol%E2%80%83Cell%E2%80%83Biol%E2%80%83Lipids%EF%BC%8C2022%EF%BC%8C1867%EF%BC%889%EF%BC%89%EF%BC%9A159182%EF%BC%8E
16、%E2%80%83%20MARAIS%E2%80%83A%E2%80%83D%EF%BC%8EApolipoprotein%E2%80%83%20E%E2%80%83%20in%E2%80%83%20lipoprotein%E2%80%83%0Ametabolism%EF%BC%8Chealth%E2%80%83and%E2%80%83cardiovascular%E2%80%83disease%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0APathology%EF%BC%8C2019%EF%BC%8C51%EF%BC%882%EF%BC%89%EF%BC%9A165-176%EF%BC%8E%E2%80%83%20MARAIS%E2%80%83A%E2%80%83D%EF%BC%8EApolipoprotein%E2%80%83%20E%E2%80%83%20in%E2%80%83%20lipoprotein%E2%80%83%0Ametabolism%EF%BC%8Chealth%E2%80%83and%E2%80%83cardiovascular%E2%80%83disease%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0APathology%EF%BC%8C2019%EF%BC%8C51%EF%BC%882%EF%BC%89%EF%BC%9A165-176%EF%BC%8E
17、RASMUSSEN%E2%80%83K%E2%80%83L%EF%BC%8CTYBJAERG-HANSEN%E2%80%83A%EF%BC%8C%0ANORDESTGAARD%E2%80%83B%E2%80%83G%EF%BC%8Cet%E2%80%83al%EF%BC%8EAPOE%E2%80%83and%E2%80%83dementia%E2%80%83-%E2%80%83%0Aresequencing%E2%80%83and%E2%80%83genotyping%E2%80%83in%E2%80%83105%EF%BC%8C597%E2%80%83individuals%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAlzheimers%E2%80%83Dement%EF%BC%8C2020%EF%BC%8C16%EF%BC%8812%EF%BC%89%EF%BC%9A%0A1624-1637%EF%BC%8ERASMUSSEN%E2%80%83K%E2%80%83L%EF%BC%8CTYBJAERG-HANSEN%E2%80%83A%EF%BC%8C%0ANORDESTGAARD%E2%80%83B%E2%80%83G%EF%BC%8Cet%E2%80%83al%EF%BC%8EAPOE%E2%80%83and%E2%80%83dementia%E2%80%83-%E2%80%83%0Aresequencing%E2%80%83and%E2%80%83genotyping%E2%80%83in%E2%80%83105%EF%BC%8C597%E2%80%83individuals%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAlzheimers%E2%80%83Dement%EF%BC%8C2020%EF%BC%8C16%EF%BC%8812%EF%BC%89%EF%BC%9A%0A1624-1637%EF%BC%8E
18、DAS%E2%80%83S%EF%BC%8CKAUL%E2%80%83S%EF%BC%8CJYOTHY%E2%80%83A%EF%BC%8Cet%E2%80%83al%EF%BC%8EAssociation%E2%80%83%0Aof%E2%80%83APOE%EF%BC%88E2%EF%BC%8CE3%E2%80%83and%E2%80%83E4%EF%BC%89gene%E2%80%83variants%E2%80%83and%E2%80%83lipid%E2%80%83%0Alevels%E2%80%83in%E2%80%83ischemic%E2%80%83stroke%EF%BC%8Cits%E2%80%83subtypes%E2%80%83and%E2%80%83hemorrhagic%E2%80%83%0Astroke%E2%80%83in%E2%80%83a%E2%80%83South%E2%80%83Indian%E2%80%83population%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENeurosci%E2%80%83%0ALett%EF%BC%8C2016%EF%BC%88628%EF%BC%89%EF%BC%9A136-141%EF%BC%8EDAS%E2%80%83S%EF%BC%8CKAUL%E2%80%83S%EF%BC%8CJYOTHY%E2%80%83A%EF%BC%8Cet%E2%80%83al%EF%BC%8EAssociation%E2%80%83%0Aof%E2%80%83APOE%EF%BC%88E2%EF%BC%8CE3%E2%80%83and%E2%80%83E4%EF%BC%89gene%E2%80%83variants%E2%80%83and%E2%80%83lipid%E2%80%83%0Alevels%E2%80%83in%E2%80%83ischemic%E2%80%83stroke%EF%BC%8Cits%E2%80%83subtypes%E2%80%83and%E2%80%83hemorrhagic%E2%80%83%0Astroke%E2%80%83in%E2%80%83a%E2%80%83South%E2%80%83Indian%E2%80%83population%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENeurosci%E2%80%83%0ALett%EF%BC%8C2016%EF%BC%88628%EF%BC%89%EF%BC%9A136-141%EF%BC%8E
19、ZHAO%E2%80%83T%EF%BC%8CZHONG%E2%80%83T%EF%BC%8CZHANG%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAlzheimer%E2%80%99s%E2%80%83disease%EF%BC%9ACausal%E2%80%83effect%E2%80%83%20between%E2%80%83obesity%E2%80%83%0Aand%E2%80%83APOE%E2%80%83gene%E2%80%83polymorphisms%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Mol%E2%80%83Sci%EF%BC%8C%0A2023%EF%BC%8C24%EF%BC%8817%EF%BC%89%EF%BC%9A13531%EF%BC%8EZHAO%E2%80%83T%EF%BC%8CZHONG%E2%80%83T%EF%BC%8CZHANG%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAlzheimer%E2%80%99s%E2%80%83disease%EF%BC%9ACausal%E2%80%83effect%E2%80%83%20between%E2%80%83obesity%E2%80%83%0Aand%E2%80%83APOE%E2%80%83gene%E2%80%83polymorphisms%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Mol%E2%80%83Sci%EF%BC%8C%0A2023%EF%BC%8C24%EF%BC%8817%EF%BC%89%EF%BC%9A13531%EF%BC%8E
20、WANG%E2%80%83Q%E2%80%83Y%EF%BC%8CWANG%E2%80%83W%E2%80%83J%EF%BC%8CWU%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8EMeta%02analysis%E2%80%83of%E2%80%83APOE%E2%80%83%CE%B52%2F%CE%B53%2F%CE%B54%E2%80%83%20polymorphism%E2%80%83%20and%E2%80%83%0Acerebral%E2%80%83infarction%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Neural%E2%80%83Transm%EF%BC%8C2013%EF%BC%8C%0A120%EF%BC%8810%EF%BC%89%EF%BC%9A1479-1489%EF%BC%8EWANG%E2%80%83Q%E2%80%83Y%EF%BC%8CWANG%E2%80%83W%E2%80%83J%EF%BC%8CWU%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8EMeta%02analysis%E2%80%83of%E2%80%83APOE%E2%80%83%CE%B52%2F%CE%B53%2F%CE%B54%E2%80%83%20polymorphism%E2%80%83%20and%E2%80%83%0Acerebral%E2%80%83infarction%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Neural%E2%80%83Transm%EF%BC%8C2013%EF%BC%8C%0A120%EF%BC%8810%EF%BC%89%EF%BC%9A1479-1489%EF%BC%8E
21、%E2%80%83%20YAN%E2%80%83H%E2%80%83Q%EF%BC%8CYUAN%E2%80%83Y%EF%BC%8CZHANG%E2%80%83P%EF%BC%8Cet%E2%80%83al%EF%BC%8EAssociation%E2%80%83%0Aof%E2%80%83the%E2%80%83ApoE%E2%80%83gene%E2%80%83polymorphism%E2%80%83and%E2%80%83dietary%E2%80%83factors%E2%80%83with%E2%80%83%0Acerebral%E2%80%83infarction%E2%80%83and%E2%80%83circulating%E2%80%83lipid%E2%80%83concentrations%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EGenet%E2%80%83Mol%E2%80%83Res%EF%BC%8C2015%EF%BC%8C14%EF%BC%881%EF%BC%89%EF%BC%9A665-670%EF%BC%8E%E2%80%83%20YAN%E2%80%83H%E2%80%83Q%EF%BC%8CYUAN%E2%80%83Y%EF%BC%8CZHANG%E2%80%83P%EF%BC%8Cet%E2%80%83al%EF%BC%8EAssociation%E2%80%83%0Aof%E2%80%83the%E2%80%83ApoE%E2%80%83gene%E2%80%83polymorphism%E2%80%83and%E2%80%83dietary%E2%80%83factors%E2%80%83with%E2%80%83%0Acerebral%E2%80%83infarction%E2%80%83and%E2%80%83circulating%E2%80%83lipid%E2%80%83concentrations%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EGenet%E2%80%83Mol%E2%80%83Res%EF%BC%8C2015%EF%BC%8C14%EF%BC%881%EF%BC%89%EF%BC%9A665-670%EF%BC%8E
22、ZHONG%E2%80%83Z%EF%BC%8CWU%E2%80%83H%EF%BC%8CYE%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8EAssociation%E2%80%83%20of%E2%80%83%0AAPOE%E2%80%83gene%E2%80%83polymorphisms%E2%80%83with%E2%80%83cerebral%E2%80%83infarction%E2%80%83in%E2%80%83%0Athe%E2%80%83Chinese%E2%80%83population%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMed%E2%80%83Sci%E2%80%83Monit%EF%BC%8C2018%0A%EF%BC%8824%EF%BC%89%EF%BC%9A1171-1177%EF%BC%8EZHONG%E2%80%83Z%EF%BC%8CWU%E2%80%83H%EF%BC%8CYE%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8EAssociation%E2%80%83%20of%E2%80%83%0AAPOE%E2%80%83gene%E2%80%83polymorphisms%E2%80%83with%E2%80%83cerebral%E2%80%83infarction%E2%80%83in%E2%80%83%0Athe%E2%80%83Chinese%E2%80%83population%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMed%E2%80%83Sci%E2%80%83Monit%EF%BC%8C2018%0A%EF%BC%8824%EF%BC%89%EF%BC%9A1171-1177%EF%BC%8E
23、KHALIL%E2%80%83Y%E2%80%83A%EF%BC%8CRABES%E2%80%83J%E2%80%83P%EF%BC%8CBOILEAU%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAPOE%E2%80%83gene%E2%80%83variants%E2%80%83in%E2%80%83primary%E2%80%83dyslipidemia%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAtherosclerosis%EF%BC%8C2021%EF%BC%88328%EF%BC%89%EF%BC%9A11-22%EF%BC%8EKHALIL%E2%80%83Y%E2%80%83A%EF%BC%8CRABES%E2%80%83J%E2%80%83P%EF%BC%8CBOILEAU%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAPOE%E2%80%83gene%E2%80%83variants%E2%80%83in%E2%80%83primary%E2%80%83dyslipidemia%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAtherosclerosis%EF%BC%8C2021%EF%BC%88328%EF%BC%89%EF%BC%9A11-22%EF%BC%8E
24、MIAO%E2%80%83G%EF%BC%8CZHUO%E2%80%83D%EF%BC%8CHAN%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8EF%20r%20o%20m%E2%80%83%0Adegenerative%E2%80%83disease%E2%80%83to%E2%80%83malignant%E2%80%83tumors%EF%BC%9AInsight%E2%80%83to%E2%80%83%0Athe%E2%80%83function%E2%80%83of%E2%80%83ApoE%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiomed%E2%80%83Pharmacother%EF%BC%8C%0A2023%EF%BC%88158%EF%BC%89%EF%BC%9A114127%EF%BC%8EMIAO%E2%80%83G%EF%BC%8CZHUO%E2%80%83D%EF%BC%8CHAN%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8EF%20r%20o%20m%E2%80%83%0Adegenerative%E2%80%83disease%E2%80%83to%E2%80%83malignant%E2%80%83tumors%EF%BC%9AInsight%E2%80%83to%E2%80%83%0Athe%E2%80%83function%E2%80%83of%E2%80%83ApoE%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiomed%E2%80%83Pharmacother%EF%BC%8C%0A2023%EF%BC%88158%EF%BC%89%EF%BC%9A114127%EF%BC%8E
25、CHENG%E2%80%83Y%E2%80%83W%EF%BC%8CLIAO%E2%80%83Y%E2%80%83C%EF%BC%8CCHEN%E2%80%83C%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AContribution%E2%80%83%20of%E2%80%83%20the%E2%80%83%20APOE%E2%80%83%20genotype%E2%80%83%20to%E2%80%83%20cognitive%E2%80%83impairment%E2%80%83in%E2%80%83individuals%E2%80%83with%E2%80%83%E2%80%83NOTCH3%E2%80%83cysteine%02altering%E2%80%83variants%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Am%E2%80%83Heart%E2%80%83Assoc%EF%BC%8C2023%EF%BC%8C12%0A%EF%BC%8822%EF%BC%89%EF%BC%9Ae032689%EF%BC%8ECHENG%E2%80%83Y%E2%80%83W%EF%BC%8CLIAO%E2%80%83Y%E2%80%83C%EF%BC%8CCHEN%E2%80%83C%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AContribution%E2%80%83%20of%E2%80%83%20the%E2%80%83%20APOE%E2%80%83%20genotype%E2%80%83%20to%E2%80%83%20cognitive%E2%80%83impairment%E2%80%83in%E2%80%83individuals%E2%80%83with%E2%80%83%E2%80%83NOTCH3%E2%80%83cysteine%02altering%E2%80%83variants%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Am%E2%80%83Heart%E2%80%83Assoc%EF%BC%8C2023%EF%BC%8C12%0A%EF%BC%8822%EF%BC%89%EF%BC%9Ae032689%EF%BC%8E
26、DAVIDSON%E2%80%83Y%EF%BC%8CGIBBONS%E2%80%83L%EF%BC%8CPURANDARE%E2%80%83N%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EApolipoprotein%E2%80%83%20E%E2%80%83%20epsilon4%E2%80%83%20allele%E2%80%83frequency%E2%80%83%0Ain%E2%80%83vascular%E2%80%83dementia%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDement%E2%80%83Geriatr%E2%80%83%20Cogn%E2%80%83%0ADisord%EF%BC%8C2006%EF%BC%8C22%EF%BC%881%EF%BC%89%EF%BC%9A15-19%EF%BC%8EDAVIDSON%E2%80%83Y%EF%BC%8CGIBBONS%E2%80%83L%EF%BC%8CPURANDARE%E2%80%83N%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EApolipoprotein%E2%80%83%20E%E2%80%83%20epsilon4%E2%80%83%20allele%E2%80%83frequency%E2%80%83%0Ain%E2%80%83vascular%E2%80%83dementia%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDement%E2%80%83Geriatr%E2%80%83%20Cogn%E2%80%83%0ADisord%EF%BC%8C2006%EF%BC%8C22%EF%BC%881%EF%BC%89%EF%BC%9A15-19%EF%BC%8E
27、KLAGES%E2%80%83J%E2%80%83D%EF%BC%8CFISK%E2%80%83J%E2%80%83D%EF%BC%8CROCKWOOD%E2%80%83K%EF%BC%8E%0AAPOE%E2%80%83genotype%EF%BC%8Cvascular%E2%80%83risk%E2%80%83factors%EF%BC%8Cmemory%E2%80%83test%E2%80%83%0Aperformance%E2%80%83and%E2%80%83the%E2%80%83five-year%E2%80%83risk%E2%80%83of%E2%80%83vascular%E2%80%83cognitive%E2%80%83%0Aimpairment%E2%80%83or%E2%80%83Alzheimer%E2%80%99s%E2%80%83disease%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDement%E2%80%83%0AGeriatr%E2%80%83Cogn%E2%80%83Disord%EF%BC%8C2005%EF%BC%8C20%EF%BC%885%EF%BC%89%EF%BC%9A292-297%EF%BC%8EKLAGES%E2%80%83J%E2%80%83D%EF%BC%8CFISK%E2%80%83J%E2%80%83D%EF%BC%8CROCKWOOD%E2%80%83K%EF%BC%8E%0AAPOE%E2%80%83genotype%EF%BC%8Cvascular%E2%80%83risk%E2%80%83factors%EF%BC%8Cmemory%E2%80%83test%E2%80%83%0Aperformance%E2%80%83and%E2%80%83the%E2%80%83five-year%E2%80%83risk%E2%80%83of%E2%80%83vascular%E2%80%83cognitive%E2%80%83%0Aimpairment%E2%80%83or%E2%80%83Alzheimer%E2%80%99s%E2%80%83disease%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDement%E2%80%83%0AGeriatr%E2%80%83Cogn%E2%80%83Disord%EF%BC%8C2005%EF%BC%8C20%EF%BC%885%EF%BC%89%EF%BC%9A292-297%EF%BC%8E
28、NOGUCHI%E2%80%83S%EF%BC%8CMURAKAMI%E2%80%83K%EF%BC%8CYAMADA%E2%80%83N%EF%BC%8E%0AApolipoprotein%E2%80%83E%E2%80%83genotype%E2%80%83and%E2%80%83Alzheimer%E2%80%99s%E2%80%83disease%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8ELancet%EF%BC%8C1993%EF%BC%8C342%EF%BC%888873%EF%BC%89%EF%BC%9A737%EF%BC%8ENOGUCHI%E2%80%83S%EF%BC%8CMURAKAMI%E2%80%83K%EF%BC%8CYAMADA%E2%80%83N%EF%BC%8E%0AApolipoprotein%E2%80%83E%E2%80%83genotype%E2%80%83and%E2%80%83Alzheimer%E2%80%99s%E2%80%83disease%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8ELancet%EF%BC%8C1993%EF%BC%8C342%EF%BC%888873%EF%BC%89%EF%BC%9A737%EF%BC%8E
29、MONTAGNE%E2%80%83A%EF%BC%8CNATION%E2%80%83D%E2%80%83A%EF%BC%8CSAGARE%E2%80%83A%E2%80%83P%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8EAPOE4%E2%80%83leads%E2%80%83to%E2%80%83%20blood-brain%E2%80%83%20barrier%E2%80%83%20dysfunction%E2%80%83%0Apredicting%E2%80%83cognitive%E2%80%83decline%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENature%EF%BC%8C2020%EF%BC%8C%0A581%EF%BC%887806%EF%BC%89%EF%BC%9A71-76%EF%BC%8EMONTAGNE%E2%80%83A%EF%BC%8CNATION%E2%80%83D%E2%80%83A%EF%BC%8CSAGARE%E2%80%83A%E2%80%83P%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8EAPOE4%E2%80%83leads%E2%80%83to%E2%80%83%20blood-brain%E2%80%83%20barrier%E2%80%83%20dysfunction%E2%80%83%0Apredicting%E2%80%83cognitive%E2%80%83decline%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENature%EF%BC%8C2020%EF%BC%8C%0A581%EF%BC%887806%EF%BC%89%EF%BC%9A71-76%EF%BC%8E
30、罗伏钢,陈梅芳,章隆,等.ApoE基因多态性与脑梗死后血管性痴呆的关联性研究[J].中华全科医学,2018,16(6):874-877.罗伏钢,陈梅芳,章隆,等.ApoE基因多态性与脑梗死后血管性痴呆的关联性研究[J].中华全科医学,2018,16(6):874-877.
31、STOCKER%E2%80%83H%EF%BC%8CPERNA%E2%80%83L%EF%BC%8CWEIGL%E2%80%83K%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0APrediction%E2%80%83of%E2%80%83clinical%E2%80%83diagnosis%E2%80%83of%E2%80%83Alzheimer%E2%80%99s%E2%80%83%0Adisease%EF%BC%8Cvascular%EF%BC%8Cmixed%EF%BC%8Cand%E2%80%83%E2%80%83all-cause%E2%80%83dementia%E2%80%83%0Aby%E2%80%83%20a%E2%80%83%20polygenic%E2%80%83%20risk%E2%80%83%20score%E2%80%83%20and%E2%80%83%20APOE%E2%80%83%20status%E2%80%83%20in%E2%80%83%20a%E2%80%83%0Acommunity-based%E2%80%83%E2%80%83cohortprospectively%E2%80%83followed%E2%80%83over%E2%80%83%0A17%E2%80%83years%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMol%E2%80%83Psychiatry%EF%BC%8C2021%EF%BC%8C26%EF%BC%8810%EF%BC%89%EF%BC%9A%0A5812-5822%EF%BC%8ESTOCKER%E2%80%83H%EF%BC%8CPERNA%E2%80%83L%EF%BC%8CWEIGL%E2%80%83K%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0APrediction%E2%80%83of%E2%80%83clinical%E2%80%83diagnosis%E2%80%83of%E2%80%83Alzheimer%E2%80%99s%E2%80%83%0Adisease%EF%BC%8Cvascular%EF%BC%8Cmixed%EF%BC%8Cand%E2%80%83%E2%80%83all-cause%E2%80%83dementia%E2%80%83%0Aby%E2%80%83%20a%E2%80%83%20polygenic%E2%80%83%20risk%E2%80%83%20score%E2%80%83%20and%E2%80%83%20APOE%E2%80%83%20status%E2%80%83%20in%E2%80%83%20a%E2%80%83%0Acommunity-based%E2%80%83%E2%80%83cohortprospectively%E2%80%83followed%E2%80%83over%E2%80%83%0A17%E2%80%83years%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMol%E2%80%83Psychiatry%EF%BC%8C2021%EF%BC%8C26%EF%BC%8810%EF%BC%89%EF%BC%9A%0A5812-5822%EF%BC%8E
32、XIONG%E2%80%83M%EF%BC%8CJIANG%E2%80%83H%EF%BC%8CSERRANO%E2%80%83J%E2%80%83R%EF%BC%8Cet%E2%80%83al%EF%BC%8EAPOE%E2%80%83%0Aimmunotherapy%E2%80%83%20reduces%E2%80%83cerebral%E2%80%83amyloid%E2%80%83angiopathy%E2%80%83%0Aand%E2%80%83amyloid%E2%80%83plaques%E2%80%83while%E2%80%83%E2%80%83improving%E2%80%83cerebrovascular%E2%80%83%0Afunction%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESci%E2%80%83Transl%E2%80%83Med%EF%BC%8C2021%EF%BC%8C13%EF%BC%88581%EF%BC%89%EF%BC%9A%0Aeabd7522%EF%BC%8EXIONG%E2%80%83M%EF%BC%8CJIANG%E2%80%83H%EF%BC%8CSERRANO%E2%80%83J%E2%80%83R%EF%BC%8Cet%E2%80%83al%EF%BC%8EAPOE%E2%80%83%0Aimmunotherapy%E2%80%83%20reduces%E2%80%83cerebral%E2%80%83amyloid%E2%80%83angiopathy%E2%80%83%0Aand%E2%80%83amyloid%E2%80%83plaques%E2%80%83while%E2%80%83%E2%80%83improving%E2%80%83cerebrovascular%E2%80%83%0Afunction%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESci%E2%80%83Transl%E2%80%83Med%EF%BC%8C2021%EF%BC%8C13%EF%BC%88581%EF%BC%89%EF%BC%9A%0Aeabd7522%EF%BC%8E
33、NORDESTGAARD%E2%80%83L%E2%80%83T%EF%BC%8CCHRISTOFFERSEN%E2%80%83M%EF%BC%8C%0AFRIKKE-SCHMIDT%E2%80%83R%EF%BC%8EShared%E2%80%83%20risk%E2%80%83factors%E2%80%83%20between%E2%80%83%0Adementia%E2%80%83and%E2%80%83atherosclerotic%E2%80%83cardiovascular%E2%80%83disease%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Mol%E2%80%83Sci%EF%BC%8C2022%EF%BC%8C23%EF%BC%8817%EF%BC%89%EF%BC%9A9777%EF%BC%8ENORDESTGAARD%E2%80%83L%E2%80%83T%EF%BC%8CCHRISTOFFERSEN%E2%80%83M%EF%BC%8C%0AFRIKKE-SCHMIDT%E2%80%83R%EF%BC%8EShared%E2%80%83%20risk%E2%80%83factors%E2%80%83%20between%E2%80%83%0Adementia%E2%80%83and%E2%80%83atherosclerotic%E2%80%83cardiovascular%E2%80%83disease%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Mol%E2%80%83Sci%EF%BC%8C2022%EF%BC%8C23%EF%BC%8817%EF%BC%89%EF%BC%9A9777%EF%BC%8E
1、江西省卫生健康委科技计划(20194033)()
上一篇
下一篇
出版者信息








《广州医药》公众号
目录